Grufity logoGrufity logo

PFE

49.57USD+0.36(+0.73%)Market Closed

Pfizer Inc

Market Summary

USD49.57+0.36Market Closed
0.73%

PFE Stock Price

RSI Chart

Valuation

Market Cap

266.2B

Price/Earnings

9.08

Price/Sales

2.63

Price/Cashflow

8.46

MarketCap/EBT

8.19

Price/Sales

Profitability

EBT Margin

32.15%

Return on Equity

33.61%

Return on Assets

15.01%

Fundamentals

Revenue

Revenue (TTM)

99.7B

Revenue Y/Y

-6.04%

Revenue Q/Q

-18.4%

Earnings

Earnings (TTM)

29.8B

Earnings Y/Y

5.67%

Earnings Q/Q

-13.1%

Price Action

52 Week Range

41.0959.77
(Low)(High)

Last 7 days

2.9%

Last 30 days

5.4%

Last 90 days

9.0%

Trailing 12 Months

-5.2%

Financial Health

Current Ratio

1.42

Debt/Equity

0.05

Debt/Cashflow

8.15

Investor Care

Dividend Yield

3.35%

Dividend/Share (TTM)

1.6

Shares Dilution (1Y)

0.01%

Diluted EPS (TTM)

5.19

Peers (Alternatives to Pfizer)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
459.8B
96.0B
2.06% 14.31%
24
4.79
5.02% 7.14%
342.0B
29.2B
1.91% 42.40%
60.08
11.76
5.34% 1.02%
266.2B
99.7B
5.41% -5.22%
9.08
2.63
43.92% 53.21%
255.3B
57.2B
7.62% 41.81%
15.4
4.47
35.88% 197.59%
163.4B
46.7B
3.01% 44.34%
24.47
3.5
2.79% 223.53%
MID-CAP
5.5B
4.4B
-21.49% -13.61%
-46.93
1.26
1.80% 57.67%
SMALL-CAP
1.9B
628.4M
0.55% -65.47%
-4.08
3.1
64.35% -18.14%
1.9B
659.0M
2.39% 16.30%
32.36
2.95
16.78% -53.92%
1.5B
-
7.94% -70.92%
-0.54
1.95
-4.11% -144.36%
1.2B
112.7M
-2.59% -35.55%
-10.75
7.76
-54.94% 40.20%
1.1B
3.1M
28.10% -53.07%
-3.57
108.75
-77.09% -12.24%
1.0B
23.5M
10.54% 34.63%
-12.31
166.87
243.57% -1.04%
945.9M
373.2M
-4.86% -23.70%
4.56
2.34
-0.39% -38.45%
283.2M
49.7M
-21.20% -55.66%
-8.71
5.67
28.95% 32.80%
68.8M
2.6B
-43.99% -88.43%
-0.03
0.02
-13.88% -4855.92%

Financials for Pfizer

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-1.4%99,676101,13292,28981,28869,259
  S&GA Expenses3.8%13,11812,63212,50712,70312,362
Earnings Before Taxes3.6%33,68132,51627,67824,31120,726
Net Income1.6%29,77129,30924,96621,97919,432
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets0.0%195,350195,290184,000181,476179,188
  Current Assets4.4%70,40367,46654,42059,69357,900
    Cash Equivalents-27.1%1,2981,7802,4701,9441,966
  Inventory-9.0%9,51310,4549,9799,0598,640
  Net PPE1.3%15,44115,24415,10914,88214,436
  Goodwill-0.9%49,44149,89150,21149,20849,489
Liabilities-5.0%102,459107,821101,155104,013103,221
  Current Liabilities-6.5%44,31447,41039,26842,67141,803
    LT Debt, Current101.1%2,5661,2762601,6362,663
    LT Debt, Non Current-4.9%32,62934,29435,65636,19536,250
Shareholder's Equity6.2%92,63187,20882,42477,20175,691
  Retained Earnings5.5%122,967116,608111,193103,394102,252
  Additional Paid-In Capital0.2%91,35991,18390,84490,59189,973
Accumulated Depreciation-0.3%14,93114,96915,35815,07415,403
Shares Outstanding-0.4%5,5935,6175,609--
Minority Interest-0.8%259261261262275
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-15.4%26,59931,45434,58332,58032,291
  Share Based Compensation-13.6%1,0031,1611,0961,182950
Cashflow From Investing40.4%-13,959.00-23,408.00-20,232.00-22,546.00-11,630.00
Cashflow From Financing-54.8%-13,170.00-8,510.00-13,587.00-9,816.00-20,252.00
  Buy Backs0%2,0002,0002,00000
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on PFE?

39.6%


Probability that Pfizer stock will be more than 20% underwater in next one year

6.5%


Probability that Pfizer stock will be more than 30% underwater in next one year.

0%


Probability that Pfizer stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PFE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Pfizer was unfortunately bought at previous high price.

Returns

Cumulative Returns on PFE

11.0%


10-Year Cumulative Returns

10.1%


7-Year Cumulative Returns

10.4%


5-Year Cumulative Returns

12.9%


3-Year Cumulative Returns

What are the long-term rolling returns for PFE?

FIve years rolling returns for Pfizer.

Which funds bought or sold PFE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
ADDED
7.28
-1,503,000
12,861,000
0.53%
2022-11-23
Gould Capital, LLC
UNCHANGED
-
-
2,000
-%
2022-11-23
Invst, LLC
ADDED
2.48
-262,000
1,561,000
0.27%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-14.59
-183,092
460,000
0.28%
2022-11-23
FSB PREMIER WEALTH MANAGEMENT, INC.
ADDED
0.32
-62,000
320,000
0.19%
2022-11-22
Coombe, Bender & Co LLC
ADDED
0.27
-87,000
448,000
0.40%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
72.4
4,498,000
14,750,000
0.44%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
3,679,000
3,679,000
0.14%
2022-11-22
IHT Wealth Management, LLC
ADDED
22.07
57,000
3,084,000
0.23%
2022-11-22
SMITH CHAS P & ASSOCIATES PA CPAS
ADDED
0.64
-5,963,000
31,297,000
2.66%

1–10 of 47

Latest Funds Activity

Are funds buying PFE calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own PFE

Pfizer News

MarketWatch

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors.12 hours ago

PFE Fair Value

Recent SEC filings of Pfizer

View All Filings
Date Filed Form Type Document
Nov 16, 2022
4
Insider Trading
Nov 16, 2022
4
Insider Trading
Nov 16, 2022
4
Insider Trading
Nov 09, 2022
4
Insider Trading
Nov 09, 2022
10-Q
Quarterly Report
Nov 01, 2022
8-K
Current Report
Nov 01, 2022
4
Insider Trading
Nov 01, 2022
4
Insider Trading
Nov 01, 2022
4
Insider Trading
Oct 18, 2022
4
Insider Trading

Latest Insider Trading transactions for PFE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-07
Dolsten Mikael
ACQUIRED
2,627,260
33.2111
79,108
President R&D
2022-06-07
DAMICO JENNIFER B.
SOLD
-227,603
53.96
-4,218
SVP & Controller
2022-05-31
Denton David M
ACQUIRED
-
-
61,275
Chief Financial Officer & EVP
2022-05-16
DAMICO JENNIFER B.
SOLD
-202,000
50.5
-4,000
SVP & Controller
2022-05-13
SAHNI PAYAL
SOLD
-70,174.7
49.84
-1,408
Executive Vice President
2022-05-12
LANKLER DOUGLAS M
SOLD
-1,891,070
49.41
-38,273
Executive Vice President
2022-05-12
Carapezzi William R JR
SOLD
-1,645,400
50
-32,908
Executive Vice President
2022-05-11
Dolsten Mikael
SOLD
-3,151,550
49.3184
-63,902
President R&D
2022-05-11
SUSMAN SALLY
GIFTED
-
-
-5,000
Executive Vice President
2022-03-31
Pao William
ACQUIRED
-
-
115,897
Executive Vice President

1–10 of 50

Albert Bourla
65535
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PFE Income Statement

2022-10-02
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Oct. 02, 2022
Oct. 03, 2021
Oct. 02, 2022
Oct. 03, 2021
Income Statement [Abstract]    
Revenues[1]$ 22,638$ 24,035$ 76,040$ 57,450
Costs and expenses:    
Cost of sales[2]6,0639,93224,69621,085
Selling, informational and administrative expenses[2]3,3912,8999,0328,599
Research and development expenses[2]2,6962,6817,8136,914
Acquired in-process research and development expenses[3]5247628801,000
Amortization of intangible assets8229682,4782,743
Restructuring charges and certain acquisition-related costs199646580667
Other (income)/deductions––net(59)(1,696)1,063(4,043)
Income from continuing operations before provision/(benefit) for taxes on income[4]9,0017,84329,49820,484
Provision/(benefit) for taxes on income356(328)3,0981,603
Income from continuing operations8,6458,17126,40018,881
Discontinued operations––net of tax(21)(13)4(248)
Net income before allocation to noncontrolling interests8,6238,15926,40418,633
Less: Net income attributable to noncontrolling interests15122747
Net income attributable to Pfizer Inc. common shareholders$ 8,608$ 8,146$ 26,378$ 18,586
Earnings per common share––basic:    
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)$ 1.54$ 1.45$ 4.70$ 3.37
Discontinued operations––net of tax (in dollars per share)000(0.04)
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)1.541.454.713.32
Earnings per common share––diluted:    
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)1.511.434.603.31
Discontinued operations––net of tax (in dollars per share)000(0.04)
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)$ 1.51$ 1.42$ 4.60$ 3.27
Weighted-average shares––basic5,6075,6095,6065,597
Weighted-average shares––diluted5,7185,7255,7295,688
[1]On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See Note 1A.
[2]Exclusive of amortization of intangible assets.
[3]See Note 1D.
[4]Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $112 million in the third quarter of 2022 and $38 million in the third quarter of 2021, and $237 million in the first nine months of 2022 and $127 million in the first nine months of 2021. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $105 million of costs for the first six months of 2022, $57 million of costs in the third quarter of 2021 and $153 million of costs in the first nine months of 2021 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.

PFE Balance Sheet

2022-10-02
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Oct. 02, 2022
Dec. 31, 2021
Assets  
Cash and cash equivalents$ 1,298$ 1,944
Short-term investments34,82529,125
Trade accounts receivable, less allowance for doubtful accounts: 2022—$474; 2021—$49216,07611,479
Inventories[1]9,5139,059
Current tax assets2,5444,266
Other current assets6,1493,820
Total current assets70,40359,693
Equity-method investments9,82616,472
Long-term investments4,0625,054
Property, plant and equipment, less accumulated depreciation: 2022—$14,931; 2021—$15,07415,44114,882
Identifiable intangible assets[2],[3]28,15125,146
Goodwill[4]49,44149,208
Noncurrent deferred tax assets and other noncurrent tax assets7,1363,341
Other noncurrent assets10,8907,679
Total assets195,350181,476
Liabilities and Equity  
Short-term borrowings, including current portion of long-term debt: 2022—$2,566; 2021—$1,6364,0402,241
Trade accounts payable6,2675,578
Dividends payable2,2452,249
Income taxes payable3,0711,266
Accrued compensation and related items2,8523,332
Deferred revenues6,1913,067
Other current liabilities19,64724,939
Total current liabilities44,31442,671
Long-term debt32,62936,195
Pension benefit obligations2,7383,489
Postretirement benefit obligations222235
Noncurrent deferred tax liabilities616349
Other taxes payable9,70111,331
Other noncurrent liabilities12,2399,743
Total liabilities102,459104,013
Commitments and Contingencies
Common stock476473
Additional paid-in capital91,35990,591
Treasury stock(113,945)(111,361)
Retained earnings122,967103,394
Accumulated other comprehensive loss(8,225)(5,897)
Total Pfizer Inc. shareholders’ equity92,63177,201
Equity attributable to noncontrolling interests259262
Total equity92,89177,462
Total liabilities and equity$ 195,350$ 181,476
[1]The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.
[2]The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see Note 2A), and for IPR&D, is partially offset by an impairment (see Note 4).
[3]The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.
[4]All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see Note 1A), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.